PAC T18514
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ER_) degrader compared to PROTAC (without Ab).
CAS nr:
2158322-33-7
Purity:
98%
Molecular Weight:
1674,93
SMILES:
CN(C(COCCOCCNC(C1=CC=C(C(N2[C@@H](C)[C@H](NC([C@H](C)NC)=O)C(N(CC3=C(OC)C=CC4=C3C=CC=C4)C5=C2C=C(C#N)C=C5)=O)=O)C=C1)=O)=O)CCOC(C=C6)=CC=C6/C(C7=CC=C(OCC(C=C8)=CC=C8NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN9C(C=CC9=O)=O)=O)=O)=O)C=C7)=C(C%10=CC=CC=C%10)/CC
Formula:
C94H107N13O16
Pathway:
Others
Target:
Others
